期刊
VACCINE
卷 23, 期 17-18, 页码 2191-2196出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2005.01.063
关键词
serum bactericidal assay (SBA); outer membrane vesicle (OMV) vaccine; epidemic control
Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle (OMV) vaccine, MeNZB (TM), developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. MeNZB (TM), administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise (>= titre 8) in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination, in 96% (95% confidence interval (CI): 79-100%) of adults, 76% (95% CI: 72-80%) of children, 75% (95% CI: 69-80%) of toddlers and 74% (95% CI: 67-80%) of infants receiving MeNZB (TM). In conclusion, these findings suggest that MeNZB (TM) is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain. (c) 2005 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据